Icm Gi 07: Ibd

Front 1

4 adjectives for IBD

Back 1

chronic
idiopathic
autoimmune
inflammatory

Front 2

layers affected in UC

Back 2

mucosa
submucosa

Front 3

layers affected in CD

Back 3

all

Front 4

CD is more common in men/women

Back 4

women

Front 5

UC is more common in men/women

Back 5

men

Front 6

first peak in incidence is at ___ y.o.
2nd peak is at ___ y.o.

Back 6

15--25
50--65

Front 7

smoking is risk factor for ___, protective for ___.

Back 7

CD
UC

Front 8

appendectomy is risk factor for ___, protective for ___.

Back 8

CD
UC

Front 9

twin concordance for ___ is much higher than for ___.

Back 9

CD
UC

Front 10

___ mutations are more common in CD

Back 10

NOD2

Front 11

UC is more/less common than CD

Back 11

more

Front 12

4 UC symptoms

Back 12

bloody diarrhea
rectal bleeding
fecal urgency
lower abdominal cramping

Front 13

5 CD symptoms

Back 13

non-bloody diarrhea
perianal drainage/pus
fever
weight loss
right lower quadrant pain

Front 14

___ always has the listed symptoms, while ___ has diverse presentations

Back 14

UC
CD

Front 15

___ suggests chronic disease in IBD

Back 15

clubbing

Front 16

T/F: ESR, CRP are elevated in IBD

Back 16

true

Front 17

serum albumin is high/low in IBD

Back 17

low

Front 18

hyper/hypokalemia is present in IBD

Back 18

hypokalemia

Front 19

Ab associated with UC

Back 19

P-ANCA

Front 20

Ab associated with CD

Back 20

ASCA (anti Saccharomyces cerevisiae)

Front 21

whereas ___ predicts disease severity in ___, ____ doesn't in ___.

Back 21

ASCA
CD
P-ANCA
UC

Front 22

___ is a continuous disease, progressing from ___ to ___.

Back 22

UC
rectum
cecum

Front 23

while CD usually spares ___, unlike UC it can affect ___.

Back 23

rectum
perianus

Front 24

granulomas are present in ___

Back 24

CD

Front 25

strictures and fistulas are present in ___

Back 25

CD

Front 26

2 skin manifestations of IBD

Back 26

erythema nodosum
pyoderma gangrenosum

Front 27

bile duct disease associated with IBD. it is associated with ___ more than ___.

Back 27

primary sclerosing cholangitis
UC
CD

Front 28

3 tx for IBD

Back 28

aminosalicylates (ASA)
CS
immunomodulators

Front 29

3 colon-specific ASAs

Back 29

sulfasalazine
olsalazine
balsalazide

Front 30

___ is a CS for IBD

Back 30

budesonide

Front 31

___ is a drug for active CD

Back 31

6-mercaptopurine

Front 32

infliximab is ___ used for ___. it should be avoided in ___.

Back 32

anti-TNFa
fistulizing CD
bowel obstruction